Advertisement

Drugs

, Volume 55, Issue 6, pp 837–842 | Cite as

Amprenavir

  • Julie C. Adkins
  • Diana Faulds
Adis New Drug Profile

Summary

  • ▴ Amprenavir is a viral protease inhibitor with specificity for the HIV protease enzyme. The resistance profile of amprenavir appears to differ from that of other protease inhibitors such as saquinavir and indinavir.

  • ▴ Twelve hours after single-dose administration of amprenavir 1200mg to HIV-infected individuals, the mean plasma concentration of the drug was more than 10-fold greater than the 50% inhibitory concentration for HIV-1IIIB in peripheral blood lymphocytes.

  • ▴ In a small nonblind study, amprenavir monotherapy increased CD4+ cell count and decreased viral load in 37 patients with HIV infection and no previous exposure to protease inhibitor therapy.

  • ▴ Combination therapy comprising amprenavir and other antiretroviral agents (abacavir, zidovudine, lamivudine, indinavir, saquinavir or nelfinavir) decreased viral load and increased CD4+ cell counts in patients with HIV infection. Antiviral efficacy was maintained during up to 24 weeks’ follow-up.

  • ▴ Available data suggest that rash, headache and diarrhoea or loose stools are the most frequent adverse events associated with amprenavir therapy.

Keywords

Lamivudine Zidovudine Indinavir Saquinavir Nelfinavir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12PubMedCrossRefGoogle Scholar
  2. 2.
    Painter GR, St Clair MH, Demiranda P, et al. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94) [abstract]. Second National Conference on Human Retroviruses; 1995 Jan 29–Feb 2; Washington (DC), 167Google Scholar
  3. 3.
    Painter GR, Ching S, Reynolds D, et al. 141W 94. Drugs Future 1996 Apr; 21(4): 347–50Google Scholar
  4. 4.
    Sadler BM, Elkine M, Hanson C, et al. The safety and pharmacokinetics of 141W94: an HIV protease inhibitor [abstract]. Fifth International Conference on Clinical Aspects and Treatment of HIV Infection; 1995 Sep 26–29; CopenhagenGoogle Scholar
  5. 5.
    Sadler BM, Rawls C, Millard J, et al. Pharmacokinetics of 141W94 after multiple dosing in patients with HIV infection: a preliminary report [abstract]. Antiviral Res 1996 Apr; 30: A42Google Scholar
  6. 6.
    St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996 Jan; 29: 53–6PubMedCrossRefGoogle Scholar
  7. 7.
    Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995 Nov; 172: 1238–45CrossRefGoogle Scholar
  8. 8.
    Lazdins JK, Mestan J, Goutte G, et al. In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997 May; 175: 1063–70PubMedCrossRefGoogle Scholar
  9. 9.
    Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995 Sep; 69(9): 5228–35PubMedGoogle Scholar
  10. 10.
    Tisdale M, Myers RE, Maschera B, et al. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995 Aug; 39(8): 1704–10PubMedCrossRefGoogle Scholar
  11. 11.
    Combinations therapies, third generation protease inhibitors are most effective to date against HIV (media release). Bioworld Today 1997 Jan 28; 8(18): 1–4Google Scholar
  12. 12.
    Nishiyama M, Koishi M, Fujioka M, et al. Phase I clinical trial with a novel protease inhibitor for HIV, KVX-478, in healthy male volunteers [abstract]. Antiviral Res 1996 Apr; 30: A35Google Scholar
  13. 13.
    Vertex Pharmaceuticals Incorporated. Press Release, Vertex 1996 May 23Google Scholar
  14. 14.
    Singh R, Chang SY, Taylor LCE.In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S 9. Rapid Commun Mass Spectrom 1996; 10: 1019–26PubMedCrossRefGoogle Scholar
  15. 15.
    Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94 [abstract]. 37th ICAAC 1997 Sep 28–Oct 1; Toronto, 12Google Scholar
  16. 16.
    Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 Mar; 41(3): 654–60PubMedGoogle Scholar
  17. 17.
    Polk RE, Israel DS, Pastor A, et al. Pharmacokinetic (PK) interaction between ketoconazole (KCZ) and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers [abstract]. 37th ICAAC 1997 Sep 28–Oct 1; Toronto,12Google Scholar
  18. 18.
    McDowell JA, Sadler BM, Millard J, et al. Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV-1-patients [abstract]. 37th ICAAC; 1997 Sep 28–Oct 1; Toronto, 13Google Scholar
  19. 19.
    Ravitch JR, Walsh JS, Reese MJ, et al. In vivo and in vitro studies of the potential for drug interactions involving the antiretroviral abacavir (1592) in humans (poster no. 634). Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)Google Scholar
  20. 20.
    The 141W94 International Study Group. Preliminary data on the safety and antiviral efficacy of the novel protease inhibitor 141W94 in HIV-infected patients with 150 to 400 CD4+ cells/mm3 [abstract]. 36th ICAAC; 1996 Sept 15–18; New Orleans, Louisiana, 8Google Scholar
  21. 21.
    Bart P-A, Rizzardi GP, Gallant S, et al. Combination abacavir (1592)/amprenavir (141W94) therapy in HTV-1-infected antiretroviral-naive subjects with CD4+ counts >400 cells/ lL and viral load >5000 copies/mL (poster no. 365). Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)Google Scholar
  22. 22.
    Vertex Pharmaceuticals reports encouraging preliminary data from phase II clinical study with HIV protease inhibitor 141W94 (media release). Today’s News 1997 Oct 13; http://www.prnewswire.com
  23. 23.
    Glaxo Wellcome’s quadruple HIV therapy. Scrip Mag 1997 Oct 24(2278): 22Google Scholar
  24. 24.
    Double protease inhibitor regimens containing amprenavir show promise; investigational protease inhibitor amprenavir appears potent; well tolerated (media release). Today’s News 1998 Feb 2; http://www.prnewswire.com
  25. 25.
    Investigational anti-HIV compound abacavir (1592) with individual HIV protease inhibitors results in potent antiretroviral activity (media release). Today’s News 1998 Feb 2; http://www.prnewswire.com
  26. 26.
    Mellors J, Lederman M, Haas D, et al. Antiretroviral effects of therapy combining abacavir (1592) with HIV protease inhibitors (PIs) [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL)Google Scholar
  27. 27.
    Kost R, Cao Y, Vesanen M, et al. Combination therapy with abacavir (1592), 141W94, and AZT/3TC in subjects acutely and chronically infected with HIV-1 [abstract]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago(IL)Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations